Announcements Trials

Conditions

Other 9Gynecologic 5Genitourinary 2Breast 1Gastrointestinal 1Head & Neck 1Thoracic 1

Drug Classes

Anti-PD-1 14Second-generation nonsteroidal antiandrogen 9Anti-PD-L1 7VEGFR inhibitor 6Anti-nectin-4 ADC 5PARP inhibitor 5Pyrimidine analog 3Alkylating agent 2FGFR inhibitor 2Multi-ingredient 2Platinum agent 2Radioactive agent 2Taxane 2Adenovirus vector 1Anti-CTLA-4 1Anti-HER2 ADC 1BRAF inhibitor 1CYP17 inhibitor 1GnRH antagonist 1HIF-2a inhibitor 1IL-15 receptor alpha fusion protein 1MEK inhibitor 1Multikinase inhibitor 1RET inhibitor 1ROS1 inhibitor 1TRK inhibitor 1
Taxane × Genitourinary × Clear all

2 Announcements

2025-06-03

FDA approves darolutamide for metastatic castration-sensitive prostate cancer

Trial
ARASENS
Drugs
Nubeqa (darolutamide) · Second-generation nonsteroidal antiandrogen, docetaxel · Taxane
Condition
Genitourinary
2022-08-05

FDA approves darolutamide tablets for metastatic hormone-sensitive prostate cancer

Trial
ARASENS
Drugs
Nubeqa (darolutamide) · Second-generation nonsteroidal antiandrogen, docetaxel · Taxane
Condition
Genitourinary
Data powered by HemOnc (CC BY 4.0) Colophon âš¡